Treanda Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Alerts
• Clinical Trials
• Forums

FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)
Condition:   Relapsed/Refractory B-Cell Lymphoma Interventions:   Drug: FT522;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Bendamustine Sponsor:   Fate Therapeutics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 18, 2023 Category: Research Source Type: clinical trials

FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma
Conditions:   Diffuse Large B Cell Lymphoma;   Transformed Indolent Non-Hodgkin's Lymphoma;   Follicular Lymphoma;   Mantle Cell Lymphoma;   Marginal Zone Lymphoma Interventions:   Drug: FT596;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone;   Drug: Rituximab;   Drug: Bendamustine Sponsor:   Fate Therapeutics Withdrawn (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 6, 2023 Category: Research Source Type: clinical trials